Rezolute Inc Stock News

SAN FRANCISCO , Dec. 15, 2025 /PRNewswire/ -- On December 11, 2025, investors in Rezolute, Inc. (NASDAQ: RZLT) saw the price of their shares crater as much as 90% during intraday trading after the company revealed the failure of its Phase 3 sunRIZE trial for ersodetug ("erso"). The company has billed this drug as a potential treatment for hypoglycemia caused by hyperinsulinism ("HI").

RZLT Investors with Losses Encouraged to Contact the Firm SAN FRANCISCO , Dec. 12, 2025 /PRNewswire/ -- On December 11, 2025, investors in Rezolute, Inc. (NASDAQ: RZLT) saw the price of their shares crater as much as 90% during intraday trading after the company revealed the failure of its Phase 3 sunRIZE trial for ersodetug ("erso"). The company has billed this drug as a potential treatment fo...

SAN FRANCISCO--(BUSINESS WIRE)--On December 11, 2025, investors in Rezolute, Inc. (NASDAQ: RZLT) saw the price of their shares crater as much as 90% during intraday trading after the company revealed the failure of its Phase 3 sunRIZE trial for ersodetug (“erso”). The company has billed this drug as a potential treatment for hypoglycemia caused by hyperinsulinism (“HI”). The news, analyst moves...

LOS ANGELES--(BUSINESS WIRE)--Rezolute, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – RZLT.

NEW YORK--(BUSINESS WIRE)---- $RZLT #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rezolute, Inc. (“Rezolute” or the “Company”) (NASDAQ: RZLT). Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for i...

Rezolute, Inc. (RZLT) Discusses Phase 3 sunRIZE Study Results and Challenges in Congenital Hyperinsulinism Transcript

ATLANTA, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Rezolute, Inc. (“Rezolute” or the “Company”) (NASDAQ: RZLT) complied with federal securities laws. On December 11, 2025, Rezolute announced topline results from its Phase 3 sunRIZE study, which did not meet the primary endpoint or the key secondary endpoint. Following this news, the price of the Company's s...

Rezolute (NASDAQ:RZLT) shares fell sharply today following the announcement that its Phase 3 sunRIZE study of ersodetug for congenital hyperinsulinism (HI) did not meet its primary endpoint. The stock fell almost 90% to trade at $1.15 late morning on Thursday.